Although our result may be a small advance in cancer biology, the current study suggests that active TGF-β1 inhibitory strategies without affecting the other isoforms and its latent form may serve as relapse prevention strategy through suppression of TGF-β1-induced expression of EMT-related genes and ABC transporter in certain types of combination therapies for NSCLCs. Here, TGFB1 is linked to cancer.